MA50619A - Fusions d'immunoglobulines de transthyrétine - Google Patents

Fusions d'immunoglobulines de transthyrétine

Info

Publication number
MA50619A
MA50619A MA050619A MA50619A MA50619A MA 50619 A MA50619 A MA 50619A MA 050619 A MA050619 A MA 050619A MA 50619 A MA50619 A MA 50619A MA 50619 A MA50619 A MA 50619A
Authority
MA
Morocco
Prior art keywords
transthyretin
immunoglobulin fusions
fusions
immunoglobulin
transthyretin immunoglobulin
Prior art date
Application number
MA050619A
Other languages
English (en)
Inventor
Kenneth Walker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50619A publication Critical patent/MA50619A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
MA050619A 2017-10-04 2018-10-03 Fusions d'immunoglobulines de transthyrétine MA50619A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762568217P 2017-10-04 2017-10-04

Publications (1)

Publication Number Publication Date
MA50619A true MA50619A (fr) 2020-08-12

Family

ID=64110020

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050619A MA50619A (fr) 2017-10-04 2018-10-03 Fusions d'immunoglobulines de transthyrétine

Country Status (12)

Country Link
US (1) US20200317795A1 (fr)
EP (1) EP3692061A1 (fr)
JP (2) JP2020537506A (fr)
KR (1) KR20200059281A (fr)
CN (1) CN111164101A (fr)
AU (1) AU2018346151A1 (fr)
CA (1) CA3076630A1 (fr)
EA (1) EA202090581A1 (fr)
MA (1) MA50619A (fr)
MX (1) MX2020003549A (fr)
SG (1) SG11202003114UA (fr)
WO (1) WO2019070901A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220324924A1 (en) * 2019-07-08 2022-10-13 Amgen Inc. Multispecific transthyretin immunoglobulin fusions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
GB0601513D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
TWI636993B (zh) * 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
JP6283408B2 (ja) * 2013-03-15 2018-02-21 アムジェン インコーポレイテッド ヒトｐａｃ１抗体
CA2915386A1 (fr) 2013-06-26 2014-12-31 Amgen Inc. Proteines de liaison a l'antigene se liant aux recepteurs cb1 et leurs utilisations
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2017083604A1 (fr) 2015-11-12 2017-05-18 Amgen Inc. Amélioration pharmacocinétique médiée par la triazine de composés thérapeutiques
CN106977609B (zh) * 2017-04-19 2020-07-28 刘崇东 一种融合蛋白、制备方法及其应用

Also Published As

Publication number Publication date
MX2020003549A (es) 2020-08-03
EA202090581A1 (ru) 2020-08-31
AU2018346151A1 (en) 2020-04-02
WO2019070901A1 (fr) 2019-04-11
EP3692061A1 (fr) 2020-08-12
US20200317795A1 (en) 2020-10-08
JP2020537506A (ja) 2020-12-24
CA3076630A1 (fr) 2019-04-11
JP2024012336A (ja) 2024-01-30
KR20200059281A (ko) 2020-05-28
SG11202003114UA (en) 2020-05-28
CN111164101A (zh) 2020-05-15

Similar Documents

Publication Publication Date Title
ES2966945T3 (es) Cierre
SG11202106214YA (en) Novel anti-ccr8 antibody
MA51428A (fr) Récepteur d'antigène chimérique multivalent
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA53297A (fr) Anticorps anti-icos
DK3248986T3 (da) Variable immunoglobulindomæner
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
DK3606961T3 (da) Garp-tgf-beta-antistoffer
GB201721338D0 (en) Anti-icos Antibodies
MA46652A (fr) Polythérapie pour l'inhibition de c3
MA50174A (fr) Formules de protéines de fusion vegfr-fc
MA44074A (fr) Immunoglobulines conjuguées à la lysine c-terminale
DK3737403T3 (da) Modificerede adenovira
MA43873A (fr) Dspositif d'injection
MA51157A (fr) Récepteurs de l'interleukine darique
DK3484921T3 (da) Anti-IL-22R antistoffer
MA50619A (fr) Fusions d'immunoglobulines de transthyrétine
MA50156A (fr) Variants d'anticorps
DK3456736T3 (da) Antistofvarianter
DK3522138T3 (da) Termoplastisk rørsystem
DK3714101T3 (da) Sporskifte
DK3627028T3 (da) Fitting
DK3388969T3 (da) Søgesystem